Head and neck squamous cell carcinoma encompasses malignancies arising from the mucosal surfaces of the oral cavity, oropharynx, hypopharynx, and larynx, representing a diverse group of tumors that share squamous histology but differ substantially in their etiology, molecular characteristics, prognosis, and optimal treatment approach. Approximately 900,000 new cases are diagnosed globally each year, with tobacco and alcohol use remaining the primary etiological factors for most anatomical sites, while human papillomavirus infection has emerged as the predominant cause of oropharyngeal squamous cell carcinoma in developed countries. HPV associated oropharyngeal cancer affects a younger, healthier population than tobacco related head and neck cancer and carries a substantially better prognosis, creating a clinically and biologically distinct disease entity within the broader category.
The treatment of locally advanced head and neck squamous cell carcinoma has traditionally relied on a combination of surgery, radiation therapy, and platinum based chemotherapy, with cisplatin based concurrent chemoradiation representing the standard of care for most patients with locally advanced unresectable disease. Despite aggressive multimodal treatment, locoregional recurrence and distant metastasis occur in a substantial proportion of patients, and once recurrent or metastatic disease develops, outcomes have historically been poor, with median overall survival of 10 to 13 months with the best available chemotherapy regimens. The addition of cetuximab, an EGFR targeting monoclonal antibody, to platinum fluorouracil chemotherapy improved survival modestly but did not dramatically alter the treatment landscape for recurrent or metastatic disease. The introduction of immune checkpoint inhibitors has provided the most meaningful survival improvement in this population since the development of platinum based regimens.
Immunological Features of Head and Neck Cancer
Head and neck squamous cell carcinomas exhibit several immunological features that influence their responsiveness to immune checkpoint inhibition. PD L1 expression, assessed by the combined positive score that accounts for both tumor cell and immune cell staining, is elevated in a substantial proportion of head and neck tumors, with combined positive scores of ten or greater identifying a subpopulation with particularly favorable responses to PD 1 pathway blockade. The tumor microenvironment of head and neck squamous cell carcinoma is characterized by complex immune cell infiltration that includes CD8 positive cytotoxic T lymphocytes, regulatory T cells, and myeloid derived suppressor cells that collectively create an immunosuppressive milieu that tumors exploit to escape immune surveillance.
HPV positive oropharyngeal cancers exhibit distinct immunological features compared to HPV negative tumors, with greater T cell infiltration and different patterns of immune checkpoint molecule expression that may partly explain their better prognosis with conventional treatment and potentially influence their responsiveness to immunotherapy. Viral oncoproteins E6 and E7 are constitutively expressed in HPV positive tumors and represent highly immunogenic foreign antigens not subject to the central tolerance mechanisms that limit T cell responses to self derived tumor antigens, theoretically creating a stronger immunological target for T cell mediated tumor killing. Clinical data on differential immunotherapy efficacy between HPV positive and HPV negative head and neck cancers remain an active area of investigation.
Pembrolizumab in Recurrent or Metastatic Disease
The KEYNOTE 048 trial was the pivotal study establishing pembrolizumab in the first line treatment of recurrent or metastatic head and neck squamous cell carcinoma. The trial enrolled 882 patients with recurrent or metastatic disease not previously treated with systemic therapy in the recurrent or metastatic setting and randomized them to three arms: pembrolizumab monotherapy, pembrolizumab combined with platinum fluorouracil chemotherapy, or cetuximab combined with platinum fluorouracil chemotherapy as the control arm. Pembrolizumab monotherapy demonstrated superior overall survival compared to the cetuximab containing regimen specifically in patients with high PD L1 combined positive scores, establishing monotherapy as the preferred first line treatment for this biomarker selected population.
The combination of Keytruda with platinum fluorouracil chemotherapy demonstrated overall survival superiority over the control regimen in patients with combined positive scores of one or greater, which encompasses the majority of head and neck squamous cell carcinoma patients. These results established two distinct first line treatment standards: pembrolizumab monotherapy for patients with high PD L1 combined positive scores seeking to avoid chemotherapy toxicity, and pembrolizumab plus platinum fluorouracil for patients with high tumor burden, lower PD L1 expression, or clinical need for more rapid tumor shrinkage. The practice changing results of KEYNOTE 048 led to regulatory approvals for pembrolizumab in the first line recurrent or metastatic setting and positioned it as the backbone of treatment for this historically difficult to treat patient population.
Second Line and Beyond Treatment
Prior to pembrolizumab approval, patients with recurrent or metastatic head and neck squamous cell carcinoma who progressed after platinum based therapy had very limited effective second line options. The KEYNOTE 040 trial evaluated pembrolizumab as second line therapy in patients with platinum refractory recurrent or metastatic head and neck squamous cell carcinoma, demonstrating a median overall survival of 8.4 months compared to 6.9 months for investigator’s choice therapy including methotrexate, docetaxel, or cetuximab. While the benefit in the unselected population was modest, patients with higher PD L1 combined positive scores derived substantially greater benefit, reinforcing the importance of biomarker guided treatment selection in this disease.
The evolution from second line to first line pembrolizumab use has established a new sequencing framework for recurrent or metastatic head and neck squamous cell carcinoma treatment, where the optimal agents to use following pembrolizumab progression remain an active clinical question. The absence of defined effective second line options after pembrolizumab based first line treatment highlights the importance of ongoing clinical trial enrollment and the development of novel therapeutic strategies including bispecific antibodies, antibody drug conjugates, and combination immunotherapy approaches that may provide additional benefit in the post pembrolizumab setting.
Integration with Locoregional Treatment
The incorporation of pembrolizumab into the locoregional treatment of locally advanced head and neck squamous cell carcinoma represents an active area of clinical investigation that has yet to definitively establish new treatment standards. Multiple randomized trials are evaluating the addition of pembrolizumab to concurrent chemoradiation for locally advanced disease, based on the hypothesis that the combination of radiation induced immunogenic cell death with immune checkpoint blockade may produce synergistic anti tumor immunity capable of improving locoregional control and preventing distant metastasis. Radiation therapy alters the tumor microenvironment in ways that could enhance immunotherapy efficacy, including increased antigen presentation, recruitment of T cells to the tumor, and upregulation of PD L1 that makes the tumor more susceptible to PD 1 pathway blockade.
The appropriate patient selection, timing of pembrolizumab relative to radiation, and duration of pembrolizumab treatment in the locally advanced setting remain to be definitively established by ongoing phase III trials. The safety of concurrent pembrolizumab and radiation must also be carefully characterized, as immune related adverse events affecting the mucosal tissues of the head and neck may overlap with radiation induced mucositis and other local effects, potentially creating composite toxicity patterns that complicate management. The results of ongoing trials will determine whether the promising preclinical and early clinical signals for immunoradiation combinations translate into meaningful survival improvements for patients with locally advanced disease.
Conclusion
Head and neck squamous cell carcinoma treatment in the recurrent and metastatic setting has been fundamentally improved by the introduction of pembrolizumab, which has replaced cetuximab containing chemotherapy regimens as the standard first line treatment framework for most patients. Keytruda, whether as monotherapy for high PD L1 expressors or in combination with chemotherapy for broader populations, delivers meaningful survival benefits with a tolerable safety profile that represents a genuine advance for patients with this historically difficult to treat disease. Ongoing investigation of pembrolizumab in the locally advanced and perioperative settings and the development of effective post pembrolizumab treatment strategies will continue to expand the clinical impact of immune checkpoint inhibition in head and neck squamous cell carcinoma.
